The work was led by Professor Michio Nakaya of the Research Institute of Environmental Medicine at Nagoya University, in collaboration with colleagues from Kyushu University and Tokushima University. Their central discovery concerns the metabolic machinery that scar-forming cells rely on to manufacture collagen, the structural protein that makes up roughly a fifth of the raw material in the form of a single amino acid: proline. By disrupting the supply chain for this building block, the team found they could throttle collagen production at its source.

Fibrosis is not unique to the heart. The same runaway deposition of collagen-based scar tissue can afflict the liver, where chronic injury can progress to cirrhosis, and it is estimated to contribute to as many as 45 percent of deaths in developed countries. Despite this enormous disease burden, no definitive therapy exists that directly suppresses the fibrotic process itself. Current treatments generally manage symptoms or slow progression rather than halting the underlying cellular program that turns healthy tissue into stiff, nonfunctional scar.

To understand why the heart is so vulnerable, it helps to look at the cells responsible. After inflammation or injury, specialized cells called myofibroblasts flood into the damaged area and begin producing collagen on an industrial scale, reinforcing the wound much as rebar reinforces concrete. In the short term this is protective, preventing the weakened heart wall from rupturing under pressure. But when the response becomes chronic, the accumulating collagen stiffens the myocardium, impairs contraction, and sets the stage for heart failure, which frequently develops in patients in the months and years following a myocardial infarction.

Because approximately 20 percent of collagen consists of proline, the Nagoya-led team reasoned that the way myofibroblasts produce and supply this amino acid might be a critical vulnerability. They began by comparing genes activated by physical stress with those switched on in mouse hearts after a heart attack, searching for molecular players common to both settings. This screen identified five overlapping candidates, among them Bcat1, the gene encoding branched-chain amino acid transaminase 1. The researchers homed in on BCAT1 because its role in myofibroblasts had never been explored, leaving open the possibility that it represented an untapped therapeutic target.

What they found was striking. In healthy mouse hearts, BCAT1 was barely detectable. But after a heart attack, levels of the enzyme rose sharply in collagen-producing cells, climbing in step with the progression of fibrosis. Follow-up experiments revealed that BCAT1 activates a cellular pathway that maintains the supply of proline, effectively functioning as part of the material-delivery system that fibrotic cells use to sustain their enormous output of collagen. In other words, the enzyme does not merely accompany scarring; it helps feed it.

The causal role of BCAT1 became clear when the team studied mice genetically engineered to lack the enzyme. After suffering a heart attack, these animals produced fewer proline-related enzymes and less collagen than their normal counterparts. They developed less scar tissue and, crucially, maintained better heart function than control mice. The histological evidence was equally compelling: heart tissue sections stained with Picrosirius red, which highlights collagen in red, showed markedly reduced collagen deposition in BCAT1-deficient mice 28 days after a heart attack compared with normal mice subjected to the same injury.

Genetic deletion, however, is not a practical treatment for patients who arrive at the hospital after an attack has already happened. So the researchers turned to pharmacology, testing a BCAT1 inhibitor called ERG240 in mice following induced heart attacks. The results were notable for their timing flexibility: ERG240 administration reduced scarring and preserved heart function even when treatment began seven days after injury, during the transition from the acute inflammatory phase to the chronic fibrotic phase. This delayed-treatment window matters enormously in clinical terms, because real-world interventions almost always occur after a heart attack rather than before it. A therapy that only works prophylactically would be of limited use; one that can reverse course after fibrosis has begun is far more valuable.

The mouse findings also appear to translate to human disease. When the team analyzed human heart tissue from patients with heart failure, they found elevated BCAT1 levels linked to increased fibrosis, suggesting that a similar enzyme-driven mechanism operates in human hearts. Intriguingly, the researchers also detected higher BCAT1 levels in the livers of patients with fatty liver disease, hinting that the same proline-supply pathway may drive fibrosis in organs well beyond the heart. The team’s next step is to determine whether the BCAT1-proline pathway also promotes fibrosis in the liver and other tissues, and to develop clinically applicable BCAT1-targeted therapies while assessing their safety, optimal dosing, and efficacy.

Perhaps the most attractive feature of BCAT1 as a drug target is its selectivity. Because the enzyme is mostly absent from healthy tissue and becomes primarily active in scar-forming cells, blocking it should, in principle, suppress pathological collagen production without disturbing the normal collagen turnover that healthy organs depend on. That specificity could translate into fewer side effects than existing anti-fibrotic treatments, which often act on broader pathways and carry a heavier burden of toxicity. As Nakaya put it, “We found that BCAT1 is a new driver of excessive collagen production in the fibrotic heart by increasing the supply of proline, a major building block of collagen. Importantly, pharmacological inhibition of BCAT1 suppressed cardiac fibrosis and preserved cardiac function, even when treatment started after fibrosis had begun to develop.” If the pathway holds up in further studies across organs and eventually in human trials, a metabolic vulnerability shared by fibrotic diseases of the heart, liver, and beyond may finally have a common weak point.

Subject of Research: The role of the enzyme BCAT1 in proline-dependent collagen production and cardiac fibrosis after heart attack

Article Title: Blocking enzyme reduces heart failure risk after heart attack in mice

Article References: Blocking enzyme reduces heart failure risk after heart attack in mice. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: BCAT1, cardiac fibrosis, heart attack, heart failure, collagen, proline, myofibroblasts, ERG240, Nagoya University, Journal of Clinical Investigation, enzyme inhibitor, fatty liver disease

The research focuses on N6-methyladenosine, or m6A, the most abundant internal chemical modification found on messenger RNA in eukaryotic cells. Rather than altering the genetic code itself, m6A marks act like adjustable dimmer switches, influencing how efficiently a given transcript is processed, exported, translated, or degraded. METTL16 is one of the key writer enzymes of this system, and previous work had already implicated it in a range of cancers, from gastric and pancreatic tumors to bladder carcinoma, where it can either promote or suppress malignancy depending on the tissue context. The new study set out to determine what METTL16 does in colorectal cancer, and the answer turned out to involve a surprising metabolic detour.

The team began by measuring METTL16 levels in clinical colorectal cancer samples and in colorectal cancer cell models, using immunohistochemistry, quantitative PCR and western blotting. Across these analyses, METTL16 was consistently elevated in tumor tissue compared with healthy references. That observation raised an obvious question: was the enzyme simply a passenger, or was it actively driving the disease? To find out, the researchers used short hairpin RNA to knock down METTL16 in colorectal cancer cells and then ran a battery of functional assays, including CCK-8 viability tests, EdU proliferation assays, wound healing experiments and transwell migration and invasion chambers.

The results were striking. When METTL16 was depleted, the malignant behavior of the cancer cells collapsed on multiple fronts: they proliferated more slowly, migrated less aggressively and invaded less effectively. But the most intriguing finding emerged when the team introduced a co-culture system in which colorectal cancer cells were grown alongside CD8-positive T cells, the cytotoxic soldiers of the adaptive immune system. In the presence of METTL16-depleted tumor cells, the T cells proliferated more vigorously and secreted higher levels of three critical effector molecules: interferon-gamma, interleukin-2 and granzyme B. In other words, silencing METTL16 in the tumor made the immune cells surrounding it measurably more lethal.

This suggested that METTL16 was not merely a growth promoter inside the tumor cell but also an architect of immune evasion, helping the cancer hide from cytotoxic T lymphocytes. The next challenge was to identify the molecular bridge connecting an RNA modification enzyme to tumor metabolism and T cell function. The researchers’ attention turned to branched-chain amino acid transaminase 1, or BCAT1, an enzyme that catalyzes the first step in the breakdown of the branched-chain amino acids leucine, isoleucine and valine. BCAT1 had previously been flagged as a risk factor in multiple cancers through pan-cancer analyses, and accumulating evidence indicates that branched-chain amino acid availability can reprogram glucose metabolism in CD8-positive T cells in ways that enhance their anti-tumor effector function.

Using a trio of molecular techniques, the team dissected how METTL16 controls BCAT1. RNA immunoprecipitation showed a physical association between METTL16 and the BCAT1 transcript. Methylated RNA immunoprecipitation, or MeRIP, revealed that METTL16 deposits m6A marks on BCAT1 mRNA. And mRNA stability assays demonstrated the functional consequence: the m6A modification stabilized the BCAT1 message, extending its lifespan inside the cell and thereby boosting BCAT1 protein production. Liquid chromatography tandem mass spectrometry metabolomics then confirmed that this increase in BCAT1 drove enhanced catabolism of branched-chain amino acids within the tumor cells.

To prove that BCAT1 was the critical downstream mediator rather than an incidental bystander, the researchers performed rescue experiments. When they forced overexpression of BCAT1 in METTL16-depleted colorectal cancer cells, the suppressive effects of the knockdown were largely reversed: the cells regained their malignant characteristics, and the CD8-positive T cells in the co-culture system lost their enhanced proliferative and cytotoxic responses. This gain-of-function experiment established BCAT1 as the linchpin connecting METTL16’s RNA modification activity to both tumor progression and immune suppression, effectively closing the mechanistic loop.

The story then moved from the dish to the living organism. In a xenograft mouse model, depletion of METTL16 significantly inhibited tumor growth and reduced Ki-67, a well-established marker of cellular proliferation, within the tumors. Critically, the METTL16-deficient tumors also showed enhanced infiltration by CD8-positive T cells and elevated levels of T cell effector molecules, mirroring the in vitro findings and confirming that the enzyme’s influence on anti-tumor immunity operates within the complex microenvironment of a living tumor. The convergence of cell culture, molecular biology, metabolomics and animal data gives the study an unusually complete chain of evidence for a single mechanistic axis.

The implications reach well beyond colorectal cancer. The work adds to a growing body of literature showing that RNA modifications, once considered little more than molecular noise, are master regulators of cancer metabolism and tumor immunology. Other m6A machinery components, such as the methyltransferase METTL3 and the reader protein YTHDF1, have been shown to modulate immune evasion in colorectal tumors, and METTL16 itself has previously been linked to PD-L1-mediated immune escape. What makes the new findings particularly compelling is the metabolic dimension: by consuming branched-chain amino acids through BCAT1, high-METTL16 tumors may starve infiltrating T cells of nutrients they need to sustain their attack, a form of metabolic competition that complements classical immune checkpoint mechanisms.

For patients, the study suggests several potential avenues. METTL16 or BCAT1 could serve as biomarkers to identify colorectal tumors that are particularly adept at suppressing T cell immunity, helping clinicians select candidates for immunotherapy combinations. More ambitiously, pharmacological inhibitors of METTL16 or BCAT1, or dietary and metabolic strategies that manipulate branched-chain amino acid availability, could in principle be combined with checkpoint blockade to re-energize exhausted T cells. Such applications remain distant, and the study’s findings will need validation in larger cohorts and independent models before they influence clinical practice. But the core message is clear and provocative: a single RNA-tagging enzyme can simultaneously build a faster-growing tumor and a blunter immune response, and undoing that dual sabotage may one day become a genuine therapeutic strategy against one of the world’s deadliest cancers.

Subject of Research: METTL16-mediated m6A modification of BCAT1 and branched-chain amino acid metabolism in colorectal cancer progression and CD8+ T cell immunity

Article Title: METTL16 promotes colorectal cancer progression and CD8+ T cell function through BCAT1-dependent branched-chain amino acid metabolism

Article References: Hu, Y., Li, S., Zhu, M., Lin, X., Gong, C., & Fang, Z. (2026). METTL16 promotes colorectal cancer progression and CD8+ T cell function through BCAT1-dependent branched-chain amino acid metabolism. Medical Oncology, 43(11), Article 295. https://doi.org/10.1007/s12032-026-03410-7

Image Credits: AI Generated

DOI: 10.1007/s12032-026-03410-7

Keywords: colorectal cancer, METTL16, BCAT1, m6A modification, branched-chain amino acids, CD8+ T cells, immune evasion, tumor metabolism, RNA methyltransferase, immunotherapy resistance, xenograft model, cancer epigenetics